Left ventricular mass and mechanics in mild-to-moderate hypertension: Effect of nebivolol versus telmisartan

The aim of this study was to compare the effects of nebivolol and telmisartan on left ventricular mass (LVM) and midwall mechanics in mild-to-moderate hypertension. A total of 40 patients with mild-to-moderate hypertension were randomized to receive either nebivolol (2.5 to 5.0 mg/day) or telmisarta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hypertension 2005-02, Vol.18 (2), p.171-177
Hauptverfasser:	Fountoulaki, Katerina, Dimopoulos, Vasilis, Giannakoulis, John, Zintzaras, Elias, Triposkiadis, Filippos
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists - therapeutic use Angiotensin II Type 1 Receptor Blockers - therapeutic use Antihypertensive agents Arterial hypertension. Arterial hypotension Benzimidazoles - therapeutic use Benzoates - therapeutic use Benzopyrans - therapeutic use Biological and medical sciences Blood and lymphatic vessels Blood Flow Velocity Blood Pressure - drug effects Cardiology. Vascular system Cardiovascular system Clinical manifestations. Epidemiology. Investigative techniques. Etiology Diastole Echocardiography Ethanolamines - therapeutic use Female Humans Hypertension Hypertension - diagnostic imaging Hypertension - physiopathology Male Medical sciences Middle Aged midwall mechanics Mitral Valve - physiopathology Myocardial Contraction - drug effects Nebivolol Pharmacology. Drug treatments Regional Blood Flow Severity of Illness Index telmisartan Ventricular Function, Left - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of this study was to compare the effects of nebivolol and telmisartan on left ventricular mass (LVM) and midwall mechanics in mild-to-moderate hypertension. A total of 40 patients with mild-to-moderate hypertension were randomized to receive either nebivolol (2.5 to 5.0 mg/day) or telmisartan (40 to 80 mg/day) to achieve a target diastolic blood pressure of
ISSN:	0895-7061 1879-1905 1941-7225
DOI:	10.1016/j.amjhyper.2004.08.039